Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting, which is being held May 2-4, 2024, in Savannah, Georgia.
鹰制药公司（纳斯达克股票代码：EGRX）（“Eagle” 或 “公司”）今天宣布，将在即将举行的门诊麻醉学会（SAMBA）2024年年会上发表一份正在进行的试验演讲，讨论正在进行的静脉注射氨磺必利作为从出生（足月）到17岁的儿科患者术后恶心和呕吐（PONV）预防术后恶心和呕吐（PONV）的2/3期研究 2024 年 5 月 2 日至 4 日，在佐治亚州萨凡纳举行。
"Evaluating nausea in children remains a challenging and complex process," stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. "We are therefore pleased to have this opportunity to share the details of our ongoing Phase 2/3 study evaluating amisulpride to prevent postoperative nausea and vomiting in pediatric patients at this year's SAMBA 2024 Annual Meeting. Through this study, we hope to demonstrate the potential benefit of amisulpride therapy in this pediatric patient population, and we look forward to presenting preliminary results from this study in the second half of 2025."
Eagle Pharmicals医学事务副总裁迈克·格林伯格医学博士说：“评估儿童恶心仍然是一个艰巨而复杂的过程。”“因此，我们很高兴有机会在今年的SAMBA 2024年年会上分享我们正在进行的评估氨磺必利预防儿科患者术后恶心和呕吐的2/3期研究的细节。通过这项研究，我们希望证明氨磺必利疗法对这些儿科患者群体的潜在益处，我们期待在2025年下半年公布这项研究的初步结果。”
Details of the presentations are as follows:
演讲详情如下：
| Abstract Title: | Randomized, Double-Blind, Parallel-Group Active-Controlled Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients: Trial in Progress |
| Date: | Thursday, May 2, 2024 |
| Times: | 5:10-6:10pm |
| Presenter: | Dr. Lynn Bichajian |
| 摘要标题： | 静脉注射氨磺必利预防儿科患者术后恶心和呕吐的随机、双盲、平行组主动对照的2/3期研究：试验正在进行中 |
| 日期： | 2024 年 5 月 2 日，星期四 |
| 时间： | 下午 5:10-6:10 |
| 演示者： | 林恩·比查吉安博士 |